» Articles » PMID: 29975342

A Cost Reimbursement Model for Hepatitis C Treatment Care Coordination

Abstract

Objective: To estimate the cost of delivering a hepatitis C virus care coordination program at 2 New York City health care provider organizations and describe a potential payment model for these currently nonreimbursed services.

Design: An economic evaluation of a hepatitis C care coordination program was conducted using micro-costing methods compared with macro-costing methods. A potential payment model was calculated for 3 phases: enrollment to treatment initiation, treatment initiation to treatment completion, and a bonus payment for laboratory evidence of successful treatment outcome (sustained viral response).

Setting: Two New York City health care provider organizations.

Participants: Care coordinators and peer educators delivering care coordination services were interviewed about time spent on service provision. De-identified individual-level data on study participant utilization of services were also used.

Intervention: Project INSPIRE is an innovative hepatitis C care coordination program developed by the New York City Department of Health and Mental Hygiene.

Main Outcome Measures: Average cost per participant per episode of care for 2 provider organizations and a proposed payment model.

Results: The average cost per participant at 1 provider organization was $787 ($522 nonoverhead cost, $264 overhead) per episode of care (5.6 months) and $656 ($429 nonoverhead cost, $227 overhead, 5.7 months) at the other one. The first organization had a lower macro-costing estimate ($561 vs $787) whereas the other one had a higher macro-costing estimate ($775 vs $656). In the 3-phased payment model, phase 1 reimbursement would vary between the provider organizations from approximately $280 to $400, but reimbursement for both organizations would be approximately $220 for phase 2 and approximately $185 for phase 3.

Conclusions: The cost of this 5.6-month care coordination intervention was less than $800 including overhead or less than $95 per month. A 3-phase payment model is proposed and requires further evaluation for implementation feasibility. Project INSPIRE's HCV care coordination program provides good value for a cost of less than $95 per participant per month. The payment model provides an incentive for successful cure of hepatitis C with a bonus payment; using the bonus payment to support HCV tele-mentoring expands HCV treatment capacity and empowers more primary care providers to treat their own patients with HCV.

Citing Articles

Cost of providing co-located hepatitis C treatment at a syringe service program exceeds potential reimbursement: Results from a clinical trial.

Kapadia S, Eckhardt B, Leff J, Fong C, Mateu-Gelabert P, Marks K Drug Alcohol Depend Rep. 2023; 5.

PMID: 36644226 PMC: 9836210. DOI: 10.1016/j.dadr.2022.100109.


Closing the hepatitis C treatment gap: United States strategies to improve retention in care.

Jones A, Briones C, Tran T, Moreno-Walton L, Kissinger P J Viral Hepat. 2022; 29(8):588-595.

PMID: 35545901 PMC: 9276641. DOI: 10.1111/jvh.13685.


Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs.

Gutkind S, Starbird L, Murphy S, Teixeira P, Gooden L, Matheson T Drug Alcohol Depend. 2022; 232:109265.

PMID: 35042101 PMC: 9238179. DOI: 10.1016/j.drugalcdep.2022.109265.


A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure.

Wyatt B, Perumalswami P, Mageras A, Miller M, Harty A, Ma N Hepatology. 2021; 74(6):2974-2987.

PMID: 34333777 PMC: 9299620. DOI: 10.1002/hep.32086.


Innovations in Hepatitis C Screening and Treatment.

Patel A, Bui A, Prohl E, Bhattacharya D, Wang S, Branch A Hepatol Commun. 2021; 5(3):371-386.

PMID: 33681673 PMC: 7917266. DOI: 10.1002/hep4.1646.


References
1.
Brennan-Ing M, Seidel L, Rodgers L, Ernst J, Wirth D, Tietz D . The Impact of Comprehensive Case Management on HIV Client Outcomes. PLoS One. 2016; 11(2):e0148865. PMC: 4744022. DOI: 10.1371/journal.pone.0148865. View

2.
Press M, Howe R, Schoenbaum M, Cavanaugh S, Marshall A, Baldwin L . Medicare Payment for Behavioral Health Integration. N Engl J Med. 2016; 376(5):405-407. DOI: 10.1056/NEJMp1614134. View

3.
Clements K, Clark R, Lavitas P, Kunte P, Graham C, OConnell E . Access to New Medications for Hepatitis C for Medicaid Members: A Retrospective Cohort Study. J Manag Care Spec Pharm. 2016; 22(6):714-722b. PMC: 10397595. DOI: 10.18553/jmcp.2016.22.6.714. View

4.
Saab S, Jimenez M, Fong T, Wu C, Bau S, Jamal Z . Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States. J Clin Transl Hepatol. 2016; 4(2):76-82. PMC: 4913077. DOI: 10.14218/JCTH.2016.00011. View

5.
Aceijas C, Rhodes T . Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007; 18(5):352-8. DOI: 10.1016/j.drugpo.2007.04.004. View